Stock Evaluator: Journey Medical Corporation (DERM)

Journey Medical Corporation DERM

$3.90 0.20 5.41%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 421,491
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Commentary & Analysis


Financial Summary

Share Statistics DERM Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $104.4 $433.9 23%
Shares Out (Mil) 28.1 46.5 36%
Institutional Ownership 76.7% 82.2% 46%
Float (Mil) 15.6 47.7 25%
Beta na 0.74 na
Avg Daily Volume (000s) 222 345 46%
Price Change
(52-week)
(51.9%) 52.0% 19%
Growth DERM Industry
Median
Percentile
(All Stocks)
Sales (5yr) 6.8% 6.4% 45%
Net Income (5yr) (32.9%) (1.6%) 12%
EPS (5yr) (24.2%) 15.1% 11
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (17.0%) (15.1%) 42%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials DERM Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $70 $289 23%
Net Income (TTM) (Mil) ($5) ($11) 33%
EPS (TTM) ($0.186) ($0.600) 33%
Operating Cash Flow (TTM) (Mil) ($9) ($7) 21%
Net Cash Flow (TTM) (Mil) na $1 na
Long-Term Debt (Q1) (Mil) $18 $6 32%
Enterprise Value (Q1) (Mil) $127 $331 24%
Valuation DERM Industry
Median
Percentile
(All Stocks)
P/B 3.25 2.05 71%
P/E na 24.3 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios DERM Industry
Median
Percentile
(All Stocks)
Gross Margin 65.9% 69.5% 78%
Net Margin (7.3%) 3.9% 22%
ROA (5.4%) (23.3%) 28%
ROE (17.6%) (21.8%) 24%
Liabilities to Assets 68.9% 31.2% 65%
F-Score 4 3 33%

Journey Medical Corporation did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors